- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Sanford C. Bernstein Lowers Regeneron Stock Price Target
Analysts Reduce Price Objective for Biotech Firm Amid Shifting Market Expectations
Apr. 8, 2026 at 1:54pm
Got story updates? Submit your updates here. ›
Investment firm Sanford C. Bernstein has lowered its price target for shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $925.00 to $921.00, while maintaining an 'outperform' rating on the biopharmaceutical company's stock. The revised target still represents a potential upside of over 20% from Regeneron's previous closing price.
Why it matters
Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of therapies. Analyst price target adjustments can signal shifting market expectations and influence investor sentiment around the company's future performance.
The details
In a research note issued on Wednesday, Sanford C. Bernstein analysts cited the new $921.00 price target, down from their previous $925.00 objective. The firm maintained its 'outperform' rating on Regeneron stock. Other analysts have also recently weighed in on the company, with some raising their price targets while others have lowered expectations.
- Sanford C. Bernstein issued the updated price target on Wednesday, April 8, 2026.
The players
Sanford C. Bernstein
A prominent investment research and management firm that provides analysis on public companies.
Regeneron Pharmaceuticals
A U.S.-based biotechnology company focused on discovering, developing, and commercializing new medicines for serious medical conditions.
The takeaway
Regeneron's stock price has been volatile as the biotech industry navigates shifting market conditions. This latest price target adjustment from a prominent analyst firm suggests some uncertainty around the company's near-term outlook, though the 'outperform' rating indicates continued long-term optimism.
